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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPERCardiac Complications of Thoracic Irradiation 2319
Catherine Jaworski, Justin A. Mariani, Greg Wheeler, David M. Kaye
Adjuvant radiation therapy in the management of early stage breast cancer, Hodgkin’s
disease (HD), and, to a lesser extent, other thoracic malignancies has led to a signiﬁcant
improvement in disease-speciﬁc survival. Cardiovascular disease is now the most common
nonmalignancy cause of death in radiation-treated cancer survivors, often occurring decades
after treatment. Jaworski and colleagues review the spectrum of radiation-induced cardiac
disease, which includes coronary artery disease, congestive heart failure, valvular heart disease,
pericardial disease, conduction abnormalities, and sudden cardiac death. Awareness and early
identiﬁcation of potential cardiac complications is crucial in cancer survivors and the potential
utility of various screening strategies is reviewed.CLINICAL RESEARCH CLINICAL TRIALSSmall Study Shows Beneﬁt for Autlogous Cardiopoietic Stem Cell Therapy 2329
Jozef Bartunek, Atta Behfar, Dariouch Dolatabadi, Marc Vanderheyden, Miodrag Ostojic, Jo Dens,
Badih El Nakadi, Marko Banovic, Branko Beleslin, Mathias Vrolix, Victor Legrand, Christian Vrints,
Jean Louis Vanoverschelde, Ruben Crespo-Diaz, Christian Homsy, Michal Tendera, Scott Waldman,
William Wijns, Andre Terzic
The prospective, multicenter, randomized C-CURE trial randomized patients with heart
failure of ischemic origin to standard-of-care or standard-of-care plus lineage-speciﬁc stem
cells. In the cell therapy arm, bone marrow was harvested from each patient and isolated
mesenchymal stem cells were then exposed to a cardiogenic cocktail. The cardiopoietic stem
cells were then delivered by endomyocardial injections. Cell therapy was associated with
improved left ventricular ejection fraction, decreased left ventricular end-systolic volume, and
improved 6-min walk distance. This preliminary trial suggests that cardiopoietic stem cell
therapy is feasible and safe and may improve outcomes in patients with chronic ischemic
heart failure.
Editorial Comment: Charles E. Murry, Nathan J. Palpant, W. Robb MacLellan, p. 2339(continued on page A-26)
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Joel A. Lardizabal, Brian P. O’Neill, Harit V. Desai, Conrad J. Macon, Alexis P. Rodriguez,
Claudia A. Martinez, Carlos E. Alfonso, Martin S. Bilsker, Roger G. Carillo, Mauricio G. Cohen,
Alan W. Heldman, William W. O’Neill, Donald B. Williams
Lardizabal and colleagues investigated the technical feasibility and safety of a transaortic
(TAO) transcatheter aortic valve replacement (TAVR) approach in patients with inadequate
transfemoral access. The TAO technique involved a small incision above the sternal
notch and a partial sternotomy to expose the ascending aorta which was then cannulated.
Compared to a cohort of patients who underwent transapical (TAP) TAVR, the rates of
VARC-deﬁned device success and the 30-day combined safety endpoint were similar. The
TAO approach was associated with a lower combined bleeding and vascular event rate,
shorter median intensive care unit length of stay, and a favorable learning curve. The results
suggest that TAO access may be superior to a TAP approach for TAVR patients with
inadequate transfemoral access.CARDIOVASCULAR RISKSedentary Behavior Increases Cardiac Risk in Women 2346
Andrea K. Chomistek, JoAnn E. Manson, Marcia L. Stefanick, Bing Lu, Megan Sands-Lincoln,
Scott B. Going, Lorena Garcia, Matthew A. Allison, Stacy T. Sims, Michael J. LaMonte,
Karen C. Johnson, Charles B. Eaton
Chomistek and colleagues investigated the relationships between sitting time and physical
activity with cardiovascular disease (CVD). Participants in the Women’s Health Initiative
Observational Study free of CVD at baseline, provided information on sedentary behavior,
deﬁned as hours of sitting per day, and usual physical activity at baseline and during
follow-up. Sitting 10 h/day was associated with increased CVD risk compared to 5 h/day.
CVD risk was highest in inactive women (1.7 MET-h/week) who also reported 10 h/day
of sitting. These results conﬁrm that prolonged sitting time is associated with increased
CVD risk, independent of leisure-time physical activity.(continued on page A-28)
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Teresa M. de Caralt, Manuel Morales-Ruiz, Rosario J. Perea, Mariano Monzó, Jordi Esteve
Angiotensin-converting enzyme inhibitors and beta-blockers prevent left ventricular systolic
dysfunction (LVSD) in animal models of anthracycline-induced cardiomyopathy. Bosch and
colleagues randomized 90 subjects prior to chemotherapy to receive enalapril and carvedilol or
to a control group. At 6 months, left ventricular ejection fraction (LVEF) did not change in
the intervention group but signiﬁcantly decreased in controls. Compared to controls, patients
in the intervention group had a lower incidence of the combined event of death or heart
failure (6.7% vs. 22%), and of death, heart failure, or a ﬁnal LVEF <45% (6.7% vs. 25%).
These results conﬁrm the ﬁndings from animal models that angiotensin-converting enzyme
inhibitors and beta-blockers prevent antrhacycline induced LVSD and suggest the need for a
larger study of their clinical efﬁcacy.
Editorial Comment: Otto A. Smiseth, Thor Edvardsen, Helge Skulstad, p. 2363CARDIAC IMAGING IN HEART FAILURELeft Ventricular Strain Imaging Improves Risk Stratiﬁcation After MI 2365Mads Ersbøll, Nana Valeur, Ulrik Madvig Mogensen, Mads Jønsson Andersen, Jacob Eifer Møller,
Eric J. Velazquez, Christian Hassager, Peter Søgaard, Lars Køber
Ersbøll and colleagues hypothesized that left ventricular global longitudinal strain (GLS)
could stratify subsequent cardiac risk after myocardial infarction (MI) in patients with left
ventricular ejection fraction (LVEF) >40%. A GLS above 14% was associated with a
3-fold increase in the risk of the combined endpoint of all-cause mortality or heart failure
hospitalization. A GLS >14 was also signiﬁcantly associated with cardiovascular death
(hazard ratio [HR]: 12.7). Assessment of GLS using a semi-automated algorithm provides
important prognostic information in patients with LVEF >40% after MI.(continued on page A-30)
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Jean-Paul Casalta, Frederique Gouriet, Alberto Riberi, Jean-Francois Avierinos, Frederic Collart,
Olivier Mundler, Didier Raoult, Franck Thuny
Saby and colleagues report on the utility of 18F-ﬂuorodeoxyglucose positron emission
tomography/computed tomography (18F-FDG PET/CT) for diagnosing prosthetic valve
endocarditis (PVE). A total of 72 consecutive patients suspected of having PVE underwent
clinical, microbiological, and echocardiographic evaluation. The ﬁnal diagnosis was deﬁned
according to the clinical and/or pathological modiﬁed Duke criteria during 3-month
follow-up. A total of 50% of patients exhibited abnormal FDG uptake around the site of the
prosthetic valve. The positive predictive value and negative predictive values were 85% and
67%. Adding abnormal FDG uptake around the prosthetic valve as a new major criterion
signiﬁcantly increased the sensitivity of the modiﬁed Duke criteria at admission [70% vs.
97%]. The results of this study support the addition of abnormal FDG uptake as a novel
major criterion for PVE.HEART RHYTHM DISORDERSQuinidine, a Life-Saving Medication for Brugada Syndrome,
Is Inaccessible in Many Countries
2383Sami Viskin, Arthur A. M. Wilde, Milton E. Guevara-Valdivia, Amin Daoulah, Andrew D. Krahn,
Douglas P. Zipes, Amir Halkin, Kalyanam Shivkumar, Noel G. Boyle, Arnon Adler, Bernard Belhassen,
Edgardo Schapachnik, Farhan Asrar, Raphael Rosso
Quinidine is the only oral medication that is effective for preventing life-threatening
ventricular arrhythmias due to Brugada syndrome and idiopathic ventricular ﬁbrillation.
However, because of its low price and restricted indication, this medication is not marketed
in many countries. Viskin and colleagues conducted a worldwide survey of quinidine
availability by contacting professional medical societies and arrhythmia specialists. A total of
273 physicians from 131 countries responded: quinidine is readily available in only 19 (14%)
countries. This medication is not accessible in 76% of countries; it is available, but only
through speciﬁc regulatory processes that require 4 to 30 days, in 10% of countries. The lack
of quinidine accessibility is a serious medical hazard in many countries.
